Horizon Pharma Reports Q2 EPS and Revenue Beat

Horizon Pharma Reports Q2 EPS and Revenue Beat

Horizon Pharma rose 21.9% in Monday’s pre-market trading after the company reported financial results for Q2, with better-than-expected earnings and revenue and increased its full-year 2017 revenue guidance above forecasts. The biopharmaceutical company posted non-GAAP earnings of $0.41 per share, compared with the prior-year period’s $0.56 per share. Analysts polled by Capital IQ were expecting EPS of $0.10. Revenue was $289.5 million, up 12% from $257.4 million in the same […]

Read More ˃